ClearPoint Neuro, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

Income Taxes (Tables)

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2025

Schedule of Components of Income Tax Expense (Benefit)

The Company adopted ASU 2023-09 “Income Taxes (Topic 740): Improvements to Income Tax Disclosures” on a prospective basis beginning with the year ended December 31, 2025. The following table presents required disclosures pursuant to ASU 2023-09 and reconciles the U.S. federal statutory tax amount to the actual global effective amount and rate for the year ended December 31, 2025.


	Year Ended December 31, 2025
	Amount (in thousands)			Percent
U.S. Federal Statutory Rate	$	(5,378	)		21.0	%
State and local income taxes, net of federal income tax effect (a)		22			-0.1	%
Foreign tax effects		33			-0.1	%
Effects of changes in tax laws or rates enacted in the current period		—			—
Effects of cross-border tax laws		—			—
Tax credits		—			—
Changes in valuation allowance		5,124			20.0	%
Nontaxable and nondeductible items
Excess share-based compensation		(41	)		0.2	%
Other		295			-1.2	%
Changes in unrecognized tax benefit		—			—
Other adjustments		—			—
Effective tax rate	$	55			-0.2	%

(a) State taxes in South Carolina, Massachusetts and New Jersey made up the majority (greater than 50%) of the tax effect in this category.

The following table presents the required disclosures prior to adoption of ASU 2023-09 and reconciles the U.S. federal statutory income tax rate to the actual global effective amount and rate for the year ended December 31, 2024.


	Year Ended December 31,
(in thousands)	2024
Income tax benefit at federal statutory rate	$	(3,992	)
Adjustments for tax effects of:
State income tax, net of federal benefit		(650	)
Permanent adjustments		305
Benefit state rate change		136
Other		144
Share-based compensation		1,336
Net operating loss write-off		216
Change in valuation allowance		2,517
Income tax expense	$	12

Schedule of Deferred Tax Assets and Liabilities

The tax effect of temporary differences and carryforwards that give rise to significant portions of the deferred income tax assets are as follows:


	Years Ended December 31,
(in thousands)	2025			2024
Deferred income tax assets:
Net operating loss carryforwards	$	64,837		$	31,776
Share-based compensation		1,300			1,390
Accrued expenses		747			295
174 Capitalization		—			4,606
Unrealized FX (gain)/loss		5			—
Other		408			267
		67,297			38,334
Less valuation allowance		(64,155	)		(38,333	)
Total deferred income tax assets		3,142			1
Deferred tax liability - property and equipment		(117	)		—
Deferred tax liability - intangibles		(3,379	)		—
Deferred tax liability - unrealized FX (gain)/loss		—			(1	)
Net deferred tax assets	$	(354	)	$	—